Φορτώνει......
A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio(®)) in cardiac surgery: the REVAKI‐1 study
AIMS: Acute kidney injury (AKI) is a common and severe complication of cardiac surgery. There is no effective prevention or treatment. Sildenafil citrate (Revatio(®), Pfizer Inc.), a phosphodiesterase type 5 inhibitor, prevents post cardiac surgery AKI in pre‐clinical studies, however its use is con...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Br J Clin Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5346869/ https://ncbi.nlm.nih.gov/pubmed/27779776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13162 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|